Compare VRE & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRE | TRVI |
|---|---|---|
| Founded | 1949 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 1995 | 2019 |
| Metric | VRE | TRVI |
|---|---|---|
| Price | $18.99 | $14.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $19.50 | ★ $21.55 |
| AVG Volume (30 Days) | ★ 956.6K | 916.5K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ 420.00 | 31.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $288,434,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.40 | N/A |
| 52 Week Low | $13.69 | $5.41 |
| 52 Week High | $19.03 | $16.12 |
| Indicator | VRE | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 65.35 | 56.04 |
| Support Level | $18.88 | $10.07 |
| Resistance Level | $19.01 | $14.57 |
| Average True Range (ATR) | 0.02 | 0.58 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 85.71 | 80.34 |
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.